Antimicrobial resistance (AMR) is reducing the effectiveness of life-saving treatments, posing a serious and growing threat to global health and undermining the foundations of modern medicine.
The latest WHO report shows that resistance to essential antibiotics, particularly among Gram-negative bacteria, is widespread, increasing and unevenly distributed. As a result first-choice treatments for common infections of the bloodstream, urinary tract and gastrointestinal tract are becoming increasingly ineffective.
The burden is greatest in low- and middle-income countries (LMICs) where AMR surveillance coverage, microbiological diagnostic capacity and access to effective alternative treatments may be limited. The combination of high resistance levels and weaker health systems disproportionately affects the most vulnerable populations.
On October 14th, 2026 the wider public had the chance to listen to several prominent speakers in the field of AMR.
The programme opened with Professor Bjørn Blomberg from the University of Bergen, who provided a global perspective on antibiotic resistance and its consequences for human health. Drawing on extensive research into infectious diseases and antimicrobial resistance, including studies in sub-Saharan Africa, Professor Blomberg addressed the scale of the problem and the measures needed to limit its spread. His research has highlighted the serious consequences of drug-resistant infections, particularly in settings where diagnostic capacity and access to effective treatment are limited.
Moving from clinical challenges to legal and policy considerations, Associate Professor Helen Yu from Swansea University, UK, explored the frameworks that shape antibiotic discovery and development. Her research focuses on intellectual property law, innovation policy and sustainable healthcare innovation. These perspectives are particularly relevant to antibiotic development, where high research costs, scientific uncertainty and limited commercial incentives create significant challenges for bringing new treatments to patients.
The importance of effective governance was addressed by Professor Lise Hellenbø Rykkja from the Faculty of Social Sciences at the University of Bergen. Her research examines crisis management, public administration and the relationship between governance capacity and public trust. AMR presents a particularly complex governance challenge: unlike sudden emergencies, it develops gradually, crosses national borders and requires sustained action from multiple sectors. Professor Rykkja’s presentation explored the importance of institutional capacity, coordination and legitimacy in responding to such long-term threats.
Dr. Stephen Hawser from International Health Management Associates (IHMA) turned the focus towards resistance surveillance. With extensive experience in antimicrobial susceptibility testing and international resistance monitoring, Dr. Hawser has contributed to research tracking the emergence and geographical distribution of resistant bacterial pathogens. His presentation highlighted the strategic role of surveillance in identifying emerging resistance trends, guiding treatment recommendations and informing public health interventions.
The programme concluded with Professor Anders Karlén from Uppsala University, Sweden, coordinator of the ENABLE-2 antibiotic development platform. Professor Karlén’s research focuses on medicinal chemistry and the discovery of new antibacterial compounds, including agents targeting Gram-negative bacteria. Through ENABLE and its successor ENABLE-2, he has helped advance collaborative approaches to early-stage antibiotic development. His presentation addressed both the scientific challenges of discovering new antibiotics and the opportunities offered by multidisciplinary research partnerships.
Together, these presentations illustrated why tackling antimicrobial resistance demands an integrated approach. From understanding the global burden of resistant infections and strengthening surveillance systems to improving governance, innovation policies and drug discovery, progress depends on collaboration across disciplines and national borders.

